BACKGROUND: Pathologically low-risk @entity1204 @entity1 do not receive postoperative treatment; however, 10-15% of these @entity1 show recurrence with poor prognosis. We evaluated the clinical importance of @entity20405 ( @entity20405 ) activity, and its significance as a novel biomarker for the prognosis and chemo-sensitivity of @entity1204 ( @entity1204 ). METHODS: @entity20405 expression and enzyme activity in 109 @entity5 samples from @entity1 with @entity1204 were examined with a cell-cycle profiling (C2P) assay. @entity20405 -specific activity ( @entity8985 ) was determined, and its relationship with clinicopathological factors and expression of Ki-67 was analysed. RESULTS: @entity20405 -specific activity was significantly correlated with Ki-67 (P=0.035), but not with any other clinicopathological characteristics. @entity8985 was significantly higher (P=0.002) in pathologically low-risk @entity1 (not receiving adjuvant chemotherapy, n=74) than in intermediate- or high-risk @entity1 (receiving adjuvant chemotherapy, n=35). In addition, @entity1 with high @entity8985 (>3.0) showed significantly (P=0.024) shorter progression-free survival (PFS) than those with low @entity8985 (<3.0). Although Ki-67 expression itself was not a marker for prognosis, the combination of high @entity8985 and high Ki-67 expression (>15%) was robustly associated with shorter PFS (P=0.015), and this combination was an independent poor prognostic factor in the low-risk group. Inversely, in the intermediate-/high-risk group, @entity1 with high @entity8985 had a tendency of a more favourable prognosis compared with @entity1 with low @entity8985 (P=0.063). CONCLUSIONS: @entity20405 -specific activity can be used as a biomarker to predict prognosis and, possibly, chemo-sensitivity. The combination of Ki-67 expression might strengthen the clinical usefulness of @entity8985 as a biomarker.

Prognostic importance of @entity20405 -specific activity as a predictive marker for recurrence in XXXX with @entity1204 , with or without adjuvant chemotherapy.

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrioid endometrial carcinoma', 'endometrial cancer', 'EEC'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity20405 :: ('1019;1021', 'Gene') :: ['CDK4/6', 'cyclin-dependent kinase 4/6', 'Cyclin-dependent kinase 4/6'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity8985 :: ('1019', 'Gene') :: ['CDK4/6SA']
@entity1 :: (9606,Species) :: ['patients']
